JP2023105147A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023105147A5 JP2023105147A5 JP2023093802A JP2023093802A JP2023105147A5 JP 2023105147 A5 JP2023105147 A5 JP 2023105147A5 JP 2023093802 A JP2023093802 A JP 2023093802A JP 2023093802 A JP2023093802 A JP 2023093802A JP 2023105147 A5 JP2023105147 A5 JP 2023105147A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- ophthalmic pharmaceutical
- pharma
- composition according
- ceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 54
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 30
- 150000003839 salts Chemical class 0.000 claims 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 20
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 19
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 19
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 19
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 19
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims 15
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 claims 13
- 229960001416 pilocarpine Drugs 0.000 claims 13
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 10
- 229920002307 Dextran Polymers 0.000 claims 10
- 108010010803 Gelatin Proteins 0.000 claims 10
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 10
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 10
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 10
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 10
- 229920002678 cellulose Polymers 0.000 claims 10
- 239000001913 cellulose Substances 0.000 claims 10
- 229920000159 gelatin Polymers 0.000 claims 10
- 239000008273 gelatin Substances 0.000 claims 10
- 235000019322 gelatine Nutrition 0.000 claims 10
- 235000011852 gelatine desserts Nutrition 0.000 claims 10
- 235000011187 glycerol Nutrition 0.000 claims 10
- 229960005150 glycerol Drugs 0.000 claims 10
- 229920002674 hyaluronan Polymers 0.000 claims 10
- 229960003160 hyaluronic acid Drugs 0.000 claims 10
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 10
- 229920000609 methyl cellulose Polymers 0.000 claims 10
- 239000001923 methylcellulose Substances 0.000 claims 10
- 235000010981 methylcellulose Nutrition 0.000 claims 10
- 229940068886 polyethylene glycol 300 Drugs 0.000 claims 10
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims 10
- 229920005862 polyol Polymers 0.000 claims 10
- 150000003077 polyols Chemical class 0.000 claims 10
- 229950008882 polysorbate Drugs 0.000 claims 10
- 229920000136 polysorbate Polymers 0.000 claims 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 10
- 229940069328 povidone Drugs 0.000 claims 10
- 229960004063 propylene glycol Drugs 0.000 claims 10
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 10
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 10
- 229920002385 Sodium hyaluronate Polymers 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 229940010747 sodium hyaluronate Drugs 0.000 claims 9
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 201000010041 presbyopia Diseases 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 5
- 238000002513 implantation Methods 0.000 claims 4
- 229960002139 pilocarpine hydrochloride Drugs 0.000 claims 4
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical group Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 230000002411 adverse Effects 0.000 claims 3
- 230000004075 alteration Effects 0.000 claims 3
- YKFROQCFVXOUPW-UHFFFAOYSA-N 4-(methylthio) aniline Chemical compound CSC1=CC=C(N)C=C1 YKFROQCFVXOUPW-UHFFFAOYSA-N 0.000 claims 2
- 206010027646 Miosis Diseases 0.000 claims 2
- 239000003889 eye drop Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 229940102223 injectable solution Drugs 0.000 claims 2
- 230000003547 miosis Effects 0.000 claims 2
- 210000004083 nasolacrimal duct Anatomy 0.000 claims 2
- 230000004297 night vision Effects 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- 229960001963 pilocarpine nitrate Drugs 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- 230000000007 visual effect Effects 0.000 claims 2
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010020675 Hypermetropia Diseases 0.000 claims 1
- 208000004350 Strabismus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004438 eyesight Effects 0.000 claims 1
- 201000006318 hyperopia Diseases 0.000 claims 1
- 230000004305 hyperopia Effects 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000001747 pupil Anatomy 0.000 claims 1
- 230000004304 visual acuity Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025139461A JP2025168426A (ja) | 2016-08-19 | 2025-08-25 | 眼科用医薬組成物及びそれに関する使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662377154P | 2016-08-19 | 2016-08-19 | |
| US62/377,154 | 2016-08-19 | ||
| JP2019508247A JP7297308B2 (ja) | 2016-08-19 | 2017-08-18 | 眼科用医薬組成物及びそれに関する使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508247A Division JP7297308B2 (ja) | 2016-08-19 | 2017-08-18 | 眼科用医薬組成物及びそれに関する使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025139461A Division JP2025168426A (ja) | 2016-08-19 | 2025-08-25 | 眼科用医薬組成物及びそれに関する使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023105147A JP2023105147A (ja) | 2023-07-28 |
| JP2023105147A5 true JP2023105147A5 (enExample) | 2024-04-17 |
Family
ID=60935566
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508247A Active JP7297308B2 (ja) | 2016-08-19 | 2017-08-18 | 眼科用医薬組成物及びそれに関する使用 |
| JP2023093802A Pending JP2023105147A (ja) | 2016-08-19 | 2023-06-07 | 眼科用医薬組成物及びそれに関する使用 |
| JP2025139461A Pending JP2025168426A (ja) | 2016-08-19 | 2025-08-25 | 眼科用医薬組成物及びそれに関する使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508247A Active JP7297308B2 (ja) | 2016-08-19 | 2017-08-18 | 眼科用医薬組成物及びそれに関する使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025139461A Pending JP2025168426A (ja) | 2016-08-19 | 2025-08-25 | 眼科用医薬組成物及びそれに関する使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9867810B1 (enExample) |
| EP (2) | EP3500255B1 (enExample) |
| JP (3) | JP7297308B2 (enExample) |
| KR (2) | KR102588499B1 (enExample) |
| CN (2) | CN116726006A (enExample) |
| AU (2) | AU2017311636B2 (enExample) |
| CA (1) | CA3031370A1 (enExample) |
| ES (1) | ES2934790T3 (enExample) |
| IL (2) | IL264664B2 (enExample) |
| MX (2) | MX2019001877A (enExample) |
| PL (1) | PL3500255T3 (enExample) |
| PT (1) | PT3500255T (enExample) |
| WO (1) | WO2018033792A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016196367A1 (en) | 2015-05-29 | 2016-12-08 | Sydnexis, Inc. | D2o stabilized pharmaceutical formulations |
| JP7297308B2 (ja) | 2016-08-19 | 2023-06-26 | オラシス ファーマシューティカルズ リミティド | 眼科用医薬組成物及びそれに関する使用 |
| BR112020021845A2 (pt) | 2018-04-24 | 2021-02-23 | Allergan, Inc. | tratamentos para presbiopia |
| US11077053B2 (en) | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
| AU2019360953A1 (en) | 2018-10-15 | 2021-05-13 | Ocuphire Pharma, Inc. | Methods and compositions for treatment of glaucoma and related conditions |
| EP3870170A4 (en) | 2018-10-26 | 2022-07-20 | Ocuphire Pharma, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA, MYDRIASIS AND OTHER EYE DISEASES |
| WO2020226915A1 (en) * | 2019-05-08 | 2020-11-12 | Harrow Ip, Llc | Pharmaceutical compositions for treating presbyopia and methods for fabricating thereof |
| MX2023002946A (es) * | 2020-09-11 | 2023-04-11 | Intratus Nevada Inc | Composiciones y metodos para tratar presbicia, hipermetropia, astigmatismo, estereopsis disminuida, y sensibilidad al contraste disminuida. |
| MX394625B (es) * | 2020-11-12 | 2025-03-24 | Cesar Alejandro Sanchez Galeana | Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia |
| CA3205883A1 (en) * | 2021-02-04 | 2022-08-11 | Gregory I. Ostrow | Ophthalmic compositions for presbyopia |
| CN115368310B (zh) | 2021-05-18 | 2025-06-27 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
| WO2023052977A1 (en) * | 2021-09-29 | 2023-04-06 | Avaca Pharma Private Limited | Compositions, methods and uses thereof |
| US20230263727A1 (en) * | 2022-01-14 | 2023-08-24 | Somerset Therapeutics, Llc | Ophthalmologically suitable low pka buffer-containing pilocarpine compositions and related methods |
| EP4471024A4 (en) * | 2022-01-29 | 2025-10-08 | Nanjing Gritpharma Co Ltd | M-CHOLINE RECEPTOR AGONIST COMPOUND, PREPARATION METHOD AND USE THEREOF |
| US11857539B2 (en) | 2022-02-09 | 2024-01-02 | Somerset Therapeutics, Llc | Gel ophthalmic formulations of pilocarpine and brimonidine compounds and related methods |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4255415A (en) | 1978-11-22 | 1981-03-10 | Schering Corporation | Polyvinyl alcohol ophthalmic gel |
| IT1229075B (it) | 1985-04-05 | 1991-07-17 | Fidia Farmaceutici | Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico |
| US4851521A (en) | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| JP2536806B2 (ja) | 1991-03-27 | 1996-09-25 | アルコン ラボラトリーズ インコーポレイテッド | ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物 |
| US5178635A (en) * | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
| US5744155A (en) | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
| US5422116A (en) | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
| SE9401109D0 (sv) | 1994-03-31 | 1994-03-31 | Leiras Oy | Opthalmic composition II |
| SE9401108D0 (sv) | 1994-03-31 | 1994-03-31 | Leiras Oy | Ophthalmic composition I |
| US6309630B1 (en) * | 1994-05-24 | 2001-10-30 | Insite Vision Incorporated | Non-steroidal anti-inflammatory ophthalmic suspensions |
| US5698533A (en) | 1994-07-26 | 1997-12-16 | Kang; Meng-Che | Ophthalmic pharmaceutical composition |
| US5612027A (en) | 1995-04-18 | 1997-03-18 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
| US5972326A (en) * | 1995-04-18 | 1999-10-26 | Galin; Miles A. | Controlled release of pharmaceuticals in the anterior chamber of the eye |
| TW389694B (en) * | 1995-08-17 | 2000-05-11 | Novartis Ag | Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics |
| CA2193149C (en) * | 1995-12-22 | 2002-04-23 | David H. Donabedian | Cationic therapuetic agents and delivery systems |
| WO1997033562A1 (en) | 1996-03-13 | 1997-09-18 | Laboratoires Merck Sharp & Dohme-Chibret Snc | Ophthalmological composition of the type which undergoes liquid-gel phase transition |
| EP0995435B1 (en) | 1997-05-14 | 2007-04-25 | Senju Pharmaceutical Co., Ltd. | Aqueous suspension preparations with excellent redispersibility |
| US6265444B1 (en) | 1997-05-23 | 2001-07-24 | Insite Vision Incorporated | Ophthalmic composition |
| US6291466B1 (en) * | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| SE0002211D0 (sv) | 2000-06-13 | 2000-06-13 | Synphora Ab | Methods and compositions for prevention of myopia |
| US20020128267A1 (en) | 2000-07-13 | 2002-09-12 | Rebanta Bandyopadhyay | Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders |
| PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| US6273092B1 (en) | 2000-09-22 | 2001-08-14 | Gerard M. Nolan | Methods for treating various eye disorders |
| US6605640B2 (en) | 2001-01-31 | 2003-08-12 | Gerard M. Nolan | Method of treating certain eye diseases |
| US6540990B2 (en) | 2000-09-22 | 2003-04-01 | Gerard M. Nolan | Physiological method of improving vision |
| US20020160988A1 (en) | 2001-02-20 | 2002-10-31 | Israel Institute For Biological Research | Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof |
| US20040058926A1 (en) | 2001-05-04 | 2004-03-25 | Rebanta Bandyopadhyay | Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders |
| AR034371A1 (es) | 2001-06-08 | 2004-02-18 | Novartis Ag | Composiciones farmaceuticas |
| US20030018382A1 (en) | 2001-07-17 | 2003-01-23 | Pflugfelder Stephen C. | Process for improving vision |
| FR2834212B1 (fr) | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
| US20050208102A1 (en) | 2003-04-09 | 2005-09-22 | Schultz Clyde L | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| JP4860475B2 (ja) | 2003-06-13 | 2012-01-25 | アルコン，インコーポレイテッド | ２種のポリマーの相乗作用的組み合わせを含む眼科用組成物 |
| ES2593113T3 (es) * | 2003-08-07 | 2016-12-05 | Allergan, Inc. | Composiciones para el suministro de agentes terapéuticos en los ojos y métodos para obtener y usar los mismos |
| US20050119262A1 (en) | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
| MXPA03011987A (es) | 2003-12-19 | 2005-06-23 | Osio Sancho Alberto | Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal. |
| EP1611879B1 (en) | 2004-07-02 | 2009-08-12 | Novagali Pharma SA | Use of emulsions for intra- and periocular injection |
| WO2006062875A1 (en) | 2004-12-08 | 2006-06-15 | Merck & Co., Inc. | Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor |
| AR062046A1 (es) * | 2006-07-25 | 2008-08-10 | Osmotica Pharmaceutical Argentina S A | Soluciones oftalmicas |
| EP1938839B1 (en) * | 2006-12-18 | 2009-08-19 | Jorge Luis Benozzi | Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia |
| JP2010513405A (ja) * | 2006-12-21 | 2010-04-30 | ノボ・ノルデイスク・エー／エス | 二量体プロラクチンレセプターリガンド |
| KR20090108723A (ko) | 2007-01-31 | 2009-10-16 | 알러간, 인코포레이티드 | 안 약물 송달을 위한 신규한 생체적합물질 및 이의 제조방법 및 용도 |
| WO2008130591A2 (en) | 2007-04-18 | 2008-10-30 | The Gi Company, Inc. | Using trefoil polypeptides to treat eye lesions associated with ophthalmic procedures |
| WO2008153746A1 (en) | 2007-05-24 | 2008-12-18 | Aciex Therapeutics, Inc. | Formulations and methods for treating dry eye |
| GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
| WO2010135731A1 (en) | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| EP2515911A4 (en) | 2009-12-23 | 2013-08-07 | Alimera Sciences Inc | METHOD FOR REDUCING THE IMPACT OF INTRAOCULAR PRESSURE RELATED TO THE INTRA-OCCULAR APPLICATION OF CORTICOSTEROIDS |
| AU2012311239B2 (en) | 2011-09-20 | 2017-10-19 | Allergan, Inc. | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
| US10507245B2 (en) | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| US10064818B2 (en) * | 2013-08-28 | 2018-09-04 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| US9089562B2 (en) * | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| ES2538551B1 (es) * | 2013-12-20 | 2016-01-13 | Eurocanarias Oftalmológica, Sl | Composición Oftálmica para la corrección de la presbicia |
| JP2017505805A (ja) * | 2014-02-11 | 2017-02-23 | オラシス ファーマシューティカルズ リミティド | 老眼矯正に使用される眼科用薬理組成物及びその投与 |
| JP7297308B2 (ja) * | 2016-08-19 | 2023-06-26 | オラシス ファーマシューティカルズ リミティド | 眼科用医薬組成物及びそれに関する使用 |
-
2017
- 2017-08-18 JP JP2019508247A patent/JP7297308B2/ja active Active
- 2017-08-18 IL IL264664A patent/IL264664B2/en unknown
- 2017-08-18 MX MX2019001877A patent/MX2019001877A/es unknown
- 2017-08-18 KR KR1020227041350A patent/KR102588499B1/ko active Active
- 2017-08-18 CN CN202310735857.7A patent/CN116726006A/zh active Pending
- 2017-08-18 CN CN201780062092.8A patent/CN109803652A/zh active Pending
- 2017-08-18 EP EP17841144.3A patent/EP3500255B1/en active Active
- 2017-08-18 PT PT178411443T patent/PT3500255T/pt unknown
- 2017-08-18 CA CA3031370A patent/CA3031370A1/en active Pending
- 2017-08-18 PL PL17841144.3T patent/PL3500255T3/pl unknown
- 2017-08-18 AU AU2017311636A patent/AU2017311636B2/en active Active
- 2017-08-18 KR KR1020197007252A patent/KR102472774B1/ko active Active
- 2017-08-18 US US15/680,967 patent/US9867810B1/en active Active
- 2017-08-18 ES ES17841144T patent/ES2934790T3/es active Active
- 2017-08-18 WO PCT/IB2017/001140 patent/WO2018033792A2/en not_active Ceased
- 2017-08-18 EP EP22209890.7A patent/EP4190328A1/en active Pending
- 2017-08-18 IL IL297367A patent/IL297367A/en unknown
- 2017-11-29 US US15/825,505 patent/US20180207136A1/en not_active Abandoned
-
2018
- 2018-07-10 US US16/032,044 patent/US10639297B2/en active Active
-
2019
- 2019-02-15 MX MX2023003124A patent/MX2023003124A/es unknown
-
2020
- 2020-03-26 US US16/831,535 patent/US11129812B2/en active Active
-
2021
- 2021-07-27 US US17/386,138 patent/US11974986B2/en active Active
-
2023
- 2023-06-07 JP JP2023093802A patent/JP2023105147A/ja active Pending
- 2023-09-07 AU AU2023226732A patent/AU2023226732A1/en not_active Abandoned
-
2024
- 2024-11-15 US US18/949,157 patent/US20250268867A1/en active Pending
-
2025
- 2025-08-25 JP JP2025139461A patent/JP2025168426A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023105147A5 (enExample) | ||
| EP3031457B1 (en) | Medicament comprising pilocarpine and brimonidine | |
| JP2019524826A5 (enExample) | ||
| Baikoff et al. | Angle-fixated anterior chamber phakic intraocular lens for myopia of-7 to-19 diopters | |
| EP2874660B1 (en) | Ophthalmic formulation and method for ameliorating presbyopia | |
| Chaudhary et al. | Contact lenses in dry eye disease and associated ocular surface disorders | |
| Rico-Del-Viejo et al. | Nonsurgical procedures for keratoconus management | |
| Hashemian et al. | Toric implantable collamer lens for high myopic astigmatism in keratoconic patients after six months | |
| CN1753683A (zh) | 预防和治疗不良眼部病症的眼用制剂 | |
| CN114585365A (zh) | 在假晶状体患者中使用拟副交感神经药物单独或与一种或多种α激动剂组合以产生多焦点 | |
| Tehrani et al. | Iris-fixated toric phakic intraocular lens: three-year follow-up | |
| Mannis et al. | Contact lens fitting in keratoconus | |
| Yang et al. | Centration and stability of small-aperture intraocular lens in aberrated eyes | |
| KR20230042077A (ko) | 노안, 원시, 난시, 감소된 입체시, 및 감소된 대비 감도를 치료하기 위한 조성물 및 방법 | |
| Doroodgar et al. | Visual outcomes of a new implantable Phakic contact lens in patients with stable keratoconus | |
| Drack et al. | Refractive surgery in children | |
| US20230210821A1 (en) | Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality | |
| Fedotova et al. | Miniscleral lenses in the treatment of patients with dry eye syndrome (first own experience) | |
| Santos et al. | Long-term improvement after the Athens protocol for advanced keratoconus with significant ectasia progression in the fellow eye | |
| Robert et al. | Indications and contraindications of Boston KPRO types I and II | |
| Leccisotti | Bioptics by angle-supported phakic lenses and photorefractive keratectomy | |
| Visser | Objective and subjective performance of scleral lenses and new advances in scleral lens technologies | |
| Cherny et al. | Contact Lens Modifications for Boston Keratoprosthesis: Novel Case Report and Review of the Literature | |
| Dick et al. | Toric phakic intraocular lens | |
| Khorrami-Nejad et al. | Management of keratoconus with contact lenses |